Other News

Bardy Diagnostics™ Receives FDA 510(k) Clearance for 14-Day Carnation Ambulatory Monitor (CAM) Patch

SEATTLE, Sept. 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for the 14-Day version of the Carnation Ambulatory Monitor (“CAM™”), the industry’s only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia […]

iRhythm Announces Collaboration with Verily to Develop Health Management Solutions for Atrial Fibrillation Patients

SAN FRANCISCO, Sept. 04, 2019 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC) today announced a collaboration with Verily, an Alphabet company, focused on the development of solutions aimed at improving the screening, diagnosis and management of patients with atrial fibrillation (AFib). This collaboration brings together iRhythm’s expertise in AI based arrhythmia […]

NobleStitch™ EL Receives Approval Of IDE To Conduct A Trial For Reduction Of Recurrent Ischemic Stroke

NOBLES MEDICAL TECHNOLOGIES II, INC. (NMT2) ANNOUNCED TODAY THE APPROVAL BY THE U.S. FDA OF ITS IDE OF NOBLESTITCH™ EL FOR PFO CLOSURE FOR REDUCTION OF RECURRENT ISCHEMIC STROKE FOUNTAIN VALLEY, Calif., Sept. 5, 2019 /PRNewswire/ — Nobles Medical Technologies II has received approval from the U.S. Food and Drug Administration (USFDA) […]

Abbott Launches World’s First Pivotal Trial to Test New Approach for Repairing Leaky Tricuspid Heart Valves

– TRILUMINATE Pivotal trial is the world’s first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation – There are currently no approved transcatheter tricuspid repair treatments, limiting options for patients with leaky tricuspid valves who are at high risk for surgery – Abbott’s […]

BioSig‘s Subsidiary NeuroClear Technologies, Inc. Raises $3.7 million

Westport, CT, Sept. 05, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that its subsidiary, NeuroClear Technologies, Inc., raised $3.7 million in an initial seed round. […]

Novoheart Holdings Inc. Reports Fourth Quarter and Fiscal 2019 Financial Results

VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) — Novoheart Holdings Inc. (“Novoheart” or the “Company”) reports financial results for the three and twelve months ended June 30, 2019. Amounts, unless specified otherwise, are expressed in Canadian dollars and are in accordance with International Financial Reporting Standards (IFRS). Ronald Li, […]

Esperion Completes Patient Enrollment in the Global CLEAR Cardiovascular Outcomes Trial for Bempedoic Acid

– 14,032 Patients are Now Fully Enrolled in the CLEAR Cardiovascular Outcomes Trial – – Expect CLEAR Cardiovascular Outcomes Trial to Conclude in the Second Half of 2022 – ANN ARBOR, Mich., Sept. 05, 2019 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR) today announced the completion of patient enrollment in the CLEAR […]

BioTelemetry, Inc. Named to Fortune Magazine’s 100 Fastest-Growing Companies List

MALVERN, Pa., Sept. 03, 2019 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT), the leading remote medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced today it has been ranked 31st on Fortune Magazine’s 100 Fastest-Growing Companies list for 2019. The […]